InvestorsHub Logo
Followers 34
Posts 14201
Boards Moderated 1
Alias Born 03/27/2014

Re: None

Saturday, 06/05/2021 12:57:34 PM

Saturday, June 05, 2021 12:57:34 PM

Post# of 24
6/3/21_MSSTF_picks_psilocybin-based_compound_MSP-1014_as_lead_clinical_candidate

MSSTF is projected to have lab-grade/Pharma-Grade psilocybin compounds available this fall. All these other psilocybin/psychedelic pennies are gonna need compounds from someone. Why not MSSTF?

MSSTF will hopefully start generating revenues later in CY21 - and is 2-3 years AHEAD of other companies - that are still going thru clinical trials where actual revenues are still 2-3 years away.

6/3/21
https://seekingalpha.com/news/3702844-mindset-pharma-picks-psilocybin-based-compound-msp-1014-as-lead-clinical-candidate

6/5/21



Mindset Pharma (OTCQB:MSSTF) has selected its lead clinical candidate, MSP-1014, a differentiated psilocybin-based compound to move forward into current good manufacturing practice ((cGMP)) compliant manufacturing and investigational new drug (IND)-enabling studies.
MSP-1014 has the potential to be a safer, more efficacious analog to psilocybin, with reduced potential side effects, the company said.
The company anticipates MSP-1014 to have the potential to treat mood disorders, including major depressive disorder, substance misuse disorders and end-of-life angst associated with terminal illnesses, including cancer.
MSP-1014 demonstrates superior preclinical characteristics in head-to-head comparison with psilocybin and its active metabolite psilocin, including increased safety and efficacy.





2/21/21 Mindset Pharma Reaches Agreement to Manufacture Large Quantity of Pharmaceutical Grade Psilocybin Using Patent-Pending Synthesis Process
https://finance.yahoo.com/news/mindset-pharma-reaches-agreement-manufacture-120000151.html

Everything posted is MY OPINION! I am making NO buy or sell recommendations here! DO YOUR OWN DUE DILIGENCE!

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.